Artiva icon - beige-01.png
 

Artiva Biotherapeutics is advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic cancers or solid tumors. Natural killer (NK) cells are part of the innate immune system and are the body’s natural, first line of defense against tumor cells and infection. Allogeneic NK cells are seen to be highly effective anti-cancer therapies without the significant safety risk associated with approved autologous T cell therapy (CART). Our current focus is specific targeting of CD20 and CD19 in B-cell lymphomas and Her2 in various solid tumors. Our ongoing research includes novel CAR-NK therapies and optimizing our NK cell product’s activity and persistence through specific gene editing.

Product
CAR Target
mAb Combination
First Indications
IND

Allogeneic Cord-Blood Derived NK-Cells (CBNK)

––––––––
CD20 / rituximab
First Indications
Q3 2020

Armored CAR-CBNK-IL15

HER2
Potentially anti-PD-L1
2nd line HER2+ Gastric Cancer
1H 2021
CD19
anti-CD20
B-cell Malignancies
2H 2021
Not Disclosed
Not Disclosed
T-cell lymphomas or leukemias
TBD
NK-related target
Potentially anti-PD-L1
Advanced NSCLC
TBD

AB-101 is an allogeneic NK cell therapy being developed for therapeutic use in combination with monoclonal antibody therapy. AB-101 is derived from US-sourced healthy donor, licensed umbilical cord blood (UCB) selected for key anti-tumor characteristics including KIR-B haplotype and homozygous F158V/V CD16 polymorphism. The proprietary manufacturing procedure results in highly active NK cells primed for anti-tumor activity and optimized for use in combination with monoclonal antibody therapy, with extremely high and consistent expression of natural high-affinity CD16. Thousands of doses of pure, cryopreserved, infusion-ready NK cells can be generated from a single UCB, and drug product is extremely consistent from donor-to-donor. AB-101 is slated to enter clinical assessment in Q3 2020 in relapsed refractory B-cell lymphoma in combination with anti-CD20 monoclonal therapy.

 

AB-201 is a CAR-NK cell therapy targeting Her2 positive solid tumors. The CAR construct has been optimized for activity within NK cells and utilizes a highly specific proprietary anti-Her2 extracellular domain. The background NK cells maintain all the preferred characteristics seen within the AB-101 product, including high expression of activating NK receptors and CD16 as well as the cryopreservation and infusion-ready formulation. The first clinical studies with AB-201 are planned for mid-2020 and include an assessment of activity in several Her2+ solid tumor types.

 
 

AB-202 is a CAR-NK cell therapy targeting CD19 positive hematopoietic malignancy. The CAR construct has been optimized for activity within NK cells and utilizes a highly specific anti-CD19 extracellular domain. The background NK cells maintain all the preferred characteristics seen in the AB-101 product, including high expression of activating NK receptors and CD16 as well as the cryopreservation and infusion-ready formulation. The first clinical studies with AB-202 are planned for the second half of 2020 and include an assessment of dual tumor-antigen targeting via combination therapy with anti-CD20 monoclonal therapy.

Artiva research is capitalizing on the unique scale of production and proprietary CAR-NK compositions to develop new proprietary CAR-NK cell therapies to address unmet needs in hematological cancers and solid tumors. We are also evaluating specific gene editing to further enhance the therapeutic activity of NK cells in the tumor microenvironment and methods of potentially enhancing in vivo persistence in the absence of patient lymphodepletion preconditioning regimens.

Collaborations and partnerships are key to advancing, accelerating, and accessing life-saving therapies.

Sign up for news updates

  • Twitter
  • LinkedIn

Privacy Policy  |  Terms
© Artiva Biotherapeutics, Inc., 2020